INTERIM

Trial description
a randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy In patients with BRAFV600 mutant stage 3 unresectable or metastatic Melanoma
Contact name
Dr Pippa Corrie
Trial start date
Friday, November 3, 2017
Trial end date
Friday, April 17, 2020
Trial tumour type
Skin & melanoma
Show on Radiotherapy
No